1. Home
  2. TWIN vs CHRS Comparison

TWIN vs CHRS Comparison

Compare TWIN & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Twin Disc Incorporated

TWIN

Twin Disc Incorporated

HOLD

Current Price

$24.68

Market Cap

320.9M

Sector

Industrials

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.17

Market Cap

209.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TWIN
CHRS
Founded
1918
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
320.9M
209.8M
IPO Year
1994
2014

Fundamental Metrics

Financial Performance
Metric
TWIN
CHRS
Price
$24.68
$1.17
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.51
AVG Volume (30 Days)
74.3K
727.9K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
0.98%
N/A
EPS Growth
N/A
472.00
EPS
1.76
N/A
Revenue
$340,738,000.00
N/A
Revenue This Year
$10.79
$73.08
Revenue Next Year
$8.43
$30.94
P/E Ratio
$13.73
N/A
Revenue Growth
15.45
N/A
52 Week Low
$8.03
$0.95
52 Week High
$24.60
$2.62

Technical Indicators

Market Signals
Indicator
TWIN
CHRS
Relative Strength Index (RSI) 63.51 32.09
Support Level $14.75 $1.15
Resistance Level N/A $1.46
Average True Range (ATR) 0.99 0.10
MACD 0.06 -0.02
Stochastic Oscillator 96.87 17.41

Price Performance

Historical Comparison
TWIN
CHRS

About TWIN Twin Disc Incorporated

Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: